AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05712681
Drug: JP-1366 20mg tablet
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T : JP-1366 20mg tablet after the meal
Trial: NCT05712681
Drug: JP-1366 20mg tablet
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R : JP-1366 20mg tablet under fasting condition
Trial: NCT06241846
Drug: YL201 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
Trial: NCT05002309
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
Trial: NCT06161493
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
Trial: NCT05660538
Drug: Placebo (matched to VX-548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-548 for oral administration.
Trial: NCT05660538
Drug: Placebo (matched to pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to pregabalin for oral administration.
Trial: NCT05759767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in this group will receive placebo once daily for 3 weeks after ESWL session.
Trial: NCT06567392
Drug: [14C] HRS-5965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
Trial: NCT04558736
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV)
Trial: NCT05849207
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
Trial: NCT05023018
Drug: NEO100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEO100 is a purified form of perillyl alcohol.
Trial: NCT06570200
Drug: PMPR+iPRF+Vit.D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: locally applied iPRF plus vitamin D in the periodontal pocket
Trial: NCT05113615
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo Respimat inhaler
Trial: NCT04756531
Drug: PF-07321332 Dose 1
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07321332 Dose 1 or Placebo
Trial: NCT06248710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
Trial: NCT03686657
Drug: Val, Cel and Met XR Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
Trial: NCT03686657
Drug: Val, Cel and Met XR High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
Trial: NCT04809805
Drug: BAY2666605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
Trial: NCT05715762
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation at 20 ppm
Trial: NCT04514835
Drug: Cisplatin+Capecitabine+Sintilimab
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months.
Trial: NCT04744103
Drug: TCA
RxNorm normalized name: RTCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a TCA peel as a treatment for their actinic cheilitis.
Trial: NCT00817609
Drug: Angongniuhuang Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of Angongniuhuang Pill
Trial: NCT00817609
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of placebo
Trial: NCT05388487
Drug: HF1K16 /Arm 45 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Trial: NCT05388487
Drug: HF1K16 /Arm 90 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Trial: NCT05388487
Drug: HF1K16 /Arm 120 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Trial: NCT05388487
Drug: HF1K16 /Arm 160 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Trial: NCT05388487
Drug: HF1K16 /Arm 120 mg or 180 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Trial: NCT06500507
Drug: QLS4131 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
Trial: NCT06247748
Drug: Rosuvastatin calcium tablets
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
Trial: NCT04910620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo only
Trial: NCT04910620
Drug: TCI378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI378 (Lactobacillus plantarum TCI378)
Trial: NCT04910620
Drug: TCI507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI507 (Lactobacillus plantarum TCI507)
Trial: NCT05994287
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.
Trial: NCT05994287
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients received celecoxib in a dose of 400 mg orally daily.
Trial: NCT05880524
Drug: Isotonic Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
Trial: NCT00000720
Drug: Globulin, Immune
RxNorm normalized name: globulin, immune
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05077969
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg (initial dose), then 200 mg capsule, BID for 5 days
Trial: NCT05077969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, QID for 14 days; capsule, BID for 5 days
Trial: NCT05620940
Drug: Vivitrol Injectable Product
RxNorm normalized name: Vivitrol Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone Long-Acting Injection
Trial: NCT05620940
Drug: IVL3004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone Long-Acting Injection
Trial: NCT05620940
Drug: IVL4002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone Long-Acting Injection
Trial: NCT05532800
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
Trial: NCT05492045
Drug: Other
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of NSCLC.
Trial: NCT05164653
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
Trial: NCT06550128
Drug: AHB-137 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHB-137 injection will be administered subcutaneously.
Trial: NCT06550128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT06637150
Drug: endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard endocrine therapy
Trial: NCT06638905
Drug: Babor Ultimate ECM Repair Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Trial: NCT06638905
Drug: Babor Cure Cream
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Trial: NCT06645223
Drug: No Interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no interventions
Trial: NCT05949385
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
Trial: NCT04892277
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04938427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat placebo-matching mini-tablets or tablets.
Trial: NCT05026801
Drug: Azithromycin plus hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
Trial: NCT05031897
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05726968
Drug: Pilocaine 2% (1.5 ml) and 25 ug fentany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).
Trial: NCT06554821
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
Trial: NCT05548283
Drug: Aminoglycoside
RxNorm normalized name: Aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
Trial: NCT05103332
Drug: Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide administered orally
Trial: NCT05103332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by subcutaneous (SC) injection
Trial: NCT06418308
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mcg of epinephrine
Trial: NCT06418308
Drug: Standardized Spinal Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
Trial: NCT05744479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for 24 weeks
Trial: NCT05509127
Drug: Modified universal adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
Trial: NCT05509127
Drug: Conventional universal adhesive
RxNorm normalized name: STATLOCK UNIVERSAL PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
Trial: NCT06607770
Drug: Karelizumab+Apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
Trial: NCT05557708
Drug: 212-Lead Pentixather
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
Trial: NCT05928169
Drug: Topical and systemic drugs
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment and follow-up will be independent on the type of treatment
Trial: NCT06173999
Drug: SHR2554/CHOEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 with CHOEP
Trial: NCT05918029
Drug: Potassium Citrate and Citric Acid Oral Solution
RxNorm normalized name: Potassium Citrate and Citric Acid Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral potassium citrate and citric acid
Trial: NCT04272034
Drug: INCB099318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
Trial: NCT04987775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo bid
Trial: NCT06571682
Drug: Inhalation anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
Trial: NCT04531579
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
Trial: NCT06252584
Drug: Vaccines, Peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
Trial: NCT06298058
Drug: SIBP-A13 formulation for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks.
Trial: NCT05195723
Drug: WP1122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT05195723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT06389123
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Trial: NCT02465008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06344247
Drug: simagliptin：Forxiga®️
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide®️ : titrated to the target dose (1 mg qw).
Trial: NCT05274477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active component
Trial: NCT06424002
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
Trial: NCT06489015
Drug: Recombinant Human Serum Albumin
RxNorm normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
Trial: NCT04861337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
Trial: NCT06539182
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of DZD8586 at 25 mg.
Trial: NCT06539182
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of DZD8586 at 50 mg.
Trial: NCT06539182
Drug: DZD8586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of DZD8586 at 75 mg.
Trial: NCT06264596
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
Trial: NCT06565117
Drug: White yu green skin lotion
RxNorm normalized name: green ash pollen extract / white ash pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
Trial: NCT06195202
Drug: AIs
RxNorm normalized name: THAIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with AIs
Trial: NCT05126303
Drug: RMC-035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for Solution for Infusion
Trial: NCT05126303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for Solution for Infusion
Trial: NCT04817189
Drug: NEPA (300mg netupitant/0.5mg palonosetron)
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
Trial: NCT04565288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (sugar pill)
Trial: NCT05701826
Drug: HRS3797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS3797 for injection, low dose
Trial: NCT05701826
Drug: HRS3797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS3797 for injection, medium dose
Trial: NCT05701826
Drug: HRS3797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS3797 for injection, high dose